Want to see IRD full AI Analyst Report?
Top Page
Opus Genetics
(NASDAQ:IRD)
Select Model
Select Model
Rating:45Neutral
Price Target:
$4.00
▼(-2.68% Downside)
Action:Reiterated
Date:10/16/26
The score is held down primarily by very weak financial performance (large ongoing losses, accelerating cash burn, and negative equity with debt) and a technically weak price trend (below key moving averages with negative MACD). Positive corporate events around encouraging clinical data and Phase 3 progress provide upside catalysts, but do not outweigh the current funding and trend risks.
Positive Factors
Commercial and regulatory validation
FDA approval provides Opus with regulatory validation and a milestone payment opportunity from an existing global licensing agreement. Viatris’ exclusive U.S. commercialization rights also give the company a potential route to product economics without requiring Opus to build the entire commercial infrastructure itself.
Negative Factors
Severe ongoing losses
Extremely negative operating and net margins show that current revenue is far from covering the company’s cost base. The decline in TTM revenue adds pressure to an already unstable earnings profile, leaving Opus dependent on successful clinical and commercial execution before profitability can become sustainable.
Read all positive and negative factors
Positive Factors
Negative Factors
Commercial and regulatory validation
FDA approval provides Opus with regulatory validation and a milestone payment opportunity from an existing global licensing agreement. Viatris’ exclusive U.S. commercialization rights also give the company a potential route to product economics without requiring Opus to build the entire commercial infrastructure itself.
Read all positive factors
Opus Genetics (IRD) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$319.47M
Dividend YieldN/A
Average Volume (3M)3.96M
Price to Earnings (P/E)―
Beta (1Y)0.67
Revenue Growth-36.09%
EPS Growth24.84%
CountryUS
Employees28
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.27
Shares Outstanding83,195,820
10 Day Avg. Volume1,911,007
30 Day Avg. Volume3,964,601
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)81.49
Price to Sales (P/S)88.10
P/FCF Ratio-35.48
Enterprise Value/Market Cap1.27
Enterprise Value/Revenue41.11
Enterprise Value/Gross Profit41.16
Enterprise Value/Ebitda-3.86
Forecast
1Y Price Target
$13.75Price Target Upside234.55% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
EPS Forecast (FY)-1.04
Revenue Forecast (FY)$11.54M
Opus Genetics Business Overview & Revenue Model
Company Description
Opus Genetics, Inc. is a clinical-stage biopharmaceutical company focused on ophthalmology. The company is dedicated to discovering and commercializing innovative therapies to address significant unmet medical needs in patients suffering from refr...
Opus Genetics Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
18
Very Negative
Cash Flow
15
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 9.86M | 14.20M | 10.99M | 19.05M | 39.85M | 589.00K |
| Gross Profit | 9.84M | 14.20M | 10.99M | 19.05M | 39.85M | 589.00K |
| EBITDA | -104.91M | -48.07M | -57.52M | -9.97M | 18.22M | -56.69M |
| Net Income | -107.61M | -49.59M | -57.53M | -9.99M | 17.89M | -56.69M |
Balance Sheet | ||||||
| Total Assets | 92.97M | 50.24M | 36.86M | 53.95M | 48.99M | 26.08M |
| Cash, Cash Equivalents and Short-Term Investments | 88.81M | 45.09M | 30.32M | 50.52M | 42.68M | 24.75M |
| Total Debt | 34.93M | 0.00 | 0.00 | 0.00 | 0.00 | 538.00K |
| Total Liabilities | 105.95M | 34.90M | 30.14M | 4.04M | 2.75M | 3.85M |
| Stockholders Equity | -12.99M | 15.35M | 6.72M | 49.91M | 46.24M | 22.22M |
Cash Flow | ||||||
| Free Cash Flow | -40.67M | -35.25M | -25.58M | -1.11M | 14.31M | -19.37M |
| Operating Cash Flow | -40.67M | -35.25M | -25.58M | -1.11M | 14.31M | -19.37M |
| Investing Cash Flow | 0.00 | 0.00 | 1.21M | 0.00 | 0.00 | -100.00K |
| Financing Cash Flow | 97.15M | 50.02M | 4.19M | 8.98M | 3.79M | 27.61M |
Opus Genetics Technical Analysis
Negative
4.11
Price Trends
4.49
Negative
4.15
Negative
4.11
Negative
Market Momentum
-0.20
Positive
33.21
Neutral
9.06
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IRD, the sentiment is Negative. The current price of 4.11 is below the 20-day moving average (MA) of 4.53, below the 50-day MA of 4.49, and below the 200-day MA of 4.11, indicating a bearish trend. The MACD of -0.20 indicates Positive momentum. The RSI at 33.21 is Neutral, neither overbought nor oversold. The STOCH value of 9.06 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IRD.
Opus Genetics Risk Analysis
Opus Genetics disclosed 56 risk factors in its most recent earnings report. Opus Genetics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Opus Genetics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | $543.97M | -10.63 | -43.57% | ― | -66.63% | 57.89% | |
53 Neutral | $419.89M | -4.48 | -23.64% | ― | -76.20% | 52.86% | |
52 Neutral | $275.50M | -0.57 | 187.62% | ― | -8.79% | -195.46% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $230.23M | -3.47 | -42.80% | ― | ― | 59.89% | |
45 Neutral | $319.47M | -3.02 | 1147.63% | ― | -36.09% | 24.84% | |
44 Neutral | $62.98M | -1.75 | -171.19% | ― | ― | 83.55% |
* Healthcare Sector Average
IRD
Opus Genetics
3.82
1.84
92.93%
OVID
Ovid Therapeutics
2.17
0.52
31.52%
STTK
Shattuck Labs
5.37
3.27
155.71%
IKT
Inhibikase Therapeutics
1.65
0.02
1.54%
SRZN
Surrozen
23.84
10.05
72.88%
BMEA
Biomea Fusion
0.84
-0.77
-47.81%
Opus Genetics Corporate Events
Business Operations and StrategyProduct-Related Announcements
Opus Genetics Advances Gene Therapy Programs With New Data
Positive
Oct 15, 2026
On October 14, 2026, Opus Genetics presented new clinical data from its OPGx-BEST1 and OPGx-LCA5 gene therapy programs at the Retina in Rio 2026 conference in Rio de Janeiro, Brazil. The disclosures highlight progress in treating inherited retinal...
Business Operations and StrategyProduct-Related Announcements
Opus Genetics Updates OPGx-BEST1 Trial Data and Outlook
Positive
Sep 11, 2026
On September 11, 2026, Opus Genetics issued a revised data presentation correcting an immaterial error in translating logMAR visual acuity into ETDRS letters for Cohort 1 of its ongoing Phase 1/2 clinical trial of OPGx-BEST1 in BEST1-related retin...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Opus Genetics Reports Positive OPGx-BEST1 Phase 1/2 Data
Positive
Sep 9, 2026
On September 9, 2026, Opus Genetics reported positive 3- and 6-month data from the low-dose Cohort 1 of its Phase 1/2 BIRD-1 trial of OPGx-BEST1 in BEST1-related retinal diseases, with all five participants showing clinically meaningful improvemen...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.